Who
Nancy Wysenski
Director
Company insider
Files Form 4 as: Director, Cytokinetics; Director, Alkermes; Director, Provention Bio; Director, Dova Pharmaceuticals; Director, Tetraphase Pharmaceuticals; Director, Inovio Pharmaceuticals; EVP, Chief Commercial Officer, Vertex Pharmaceuticals; Chief Operating Officer, Endo Pharmaceuticals Holdings.
In numbers
- Trades disclosed
- 157
- Buys
- 3
- Sells
- 8
- Bought
- $279K
- Sold
- $35.2M
- Companies
- 9
- Companies where not an officer
- 7
- First trade
- 3 May 2006
- Last trade
- 15 Jul 2026
- Last filed
- 16 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,19775 at $82.62 | filing |
| 15 Jul 2026filed 16 Jul 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,19775 at $82.62 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 15 Apr 2026filed 15 Apr 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,21095 at $65.37 | filing |
| 15 Apr 2026filed 15 Apr 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,21095 at $65.37 | filing |
| 15 Jan 2026filed 16 Jan 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,21798 at $63.44 | filing |
| 15 Jan 2026filed 16 Jan 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,21798 at $63.44 | filing |
| 15 Oct 2025filed 16 Oct 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,21799 at $62.80 | filing |
| 15 Jul 2025filed 16 Jul 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,234164 at $38.01 | filing |
| 14 May 2025filed 14 May 2025 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,880 at $0.00 | filing |
| 14 May 2025filed 14 May 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —7,333 at $0.00 | filing |
| 15 Apr 2025filed 16 Apr 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,247162 at $38.56 | filing |
| 2 Jan 2025filed 6 Jan 2025 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,214127 at $48.93 | filing |
| 1 Oct 2024filed 3 Oct 2024 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | $6,207118 at $52.60 | filing |
| 1 Jul 2024filed 3 Jul 2024 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —114 at $0.00 | filing |
| 15 May 2024filed 16 May 2024 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,636 at $0.00 | filing |
| 15 May 2024filed 16 May 2024 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —5,600 at $0.00 | filing |
News
Traders Buy High Volume of Put Options on Alkermes (NASDAQ:ALKS)ALKS · tickerreport.com · 17 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Reviewing Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)ALKS · tickerreport.com · 13 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Nancy Wysenski; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.